Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Domenico Mallardo, MD, on Anti-CTLA4 Agents in Melanoma

  • Domenico Mallardo, MD
November 14, 2019
  • SITC Street Team, Immuno Oncology, Melanoma, News

Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

 

Transcript:

I came to the SITC meeting (to talk) about my results, updating on the study of melanoma patients treated with immuno-checkpoint inhibitor. And my study was focused on the gene profile analysis on 3 different cohorts of patients treated with immunotherapy. We analyzed our group, these 3 different cohorts of patients treated with immunotherapy, dividing in patients treated with the anti-CTLA4, I’m talking about ipilimumab (Yervoy) treatment and another cohort of patients treated with anti-PD-1 in the second-line (setting) after ipilimumab progression. Another cohort of treatment naïve patients treated with an anti-PD-1 in the first-line (setting). 

(The study was in collaration with the Istituto Nazionale Tumori - IRCCS - "Fondazione G.Pascale"). When we carry out this kind of gene profile analysis and the results are very interesting because we found that there is a different kind of signature for each different cohort of patients analyzed. Moreover, in some cohorts of patients treated with anti-PD-1, we found that there are different genes that are strongly related with the outcome…

The study was carried out on tumor tissue on melanoma patients treated with immunotherapy. The next step will be in the analysis made on peripheral blood mononuclear cell (PBMC). So, I’m talking about the blood, genetics from blood just for match the different kind of results and to understand the benefit and the mechanism behind the resistance of immunotherapy.

 

What we want to do (is find) some predictive biomarkers that can be strongly related with the outcome to treatment with the immuno-checkpoint inhibitors. 

Related Articles

  • Axi-Cel Improves OS in Patients with Refractory B-Cell Lymphoma
  • Axi-Cel Improves OS in Patients with Refractory B-Cell Lymphoma
  • Axi-Cel Improves OS in Patients with Refractory B-Cell Lymphoma
  • Promising Responses from Dual-Targeting CAR T-Cell Therapy in Myeloma Support Further Exploration
  • FDA Grants Priority Review to Pembrolizumab for Non-Muscle Invasive Bladder Cancer

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".